Clinical trials: Percutaneous Coronary Intervention Patients
Periprocedural Myocardial Necrosis
Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs)
An increase in cardiac biomarkers has been shown to occur in 5% to 30% of patients after otherwise successful percutaneous coronary interventions (PCIs)(1) Apart from side-branch occlusion, intimal dissection and coronary spasm…
- Trial name
- ROMA (NCT01007279)
- Testing
- ROSUVASTATIN
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- University of Roma La Sapienza
Acute Anterior ST-Segment Elevation Myocardial Infarction
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of SGC001 injection administered in addition to…
- Trial name
- NCT07306182
- Testing
- SGC001 injection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Beijing Sungen Biomedical Technology Co., Ltd
Percutaneous Coronary Intervention
Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention
During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI.
- Trial name
- FACTPCI (NCT03476369)
- Testing
- Fentanyl, Ticagrelor 90Mg Tablet
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- The Guthrie Clinic
Coronary Artery Disease
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
Two strategies have both proven to be effective in reducing bleeding complications while preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12 inhibitor: a) DAPT de-escalation (i.e.…
- Trial name
- TAILOR BLEED (NCT05681702)
- Testing
- aspirin plus clopidogrel, prasugrel or ticagrelor
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Florida
Coronary Artery Disease
Drug-Coated Balloon in Patients With High Bleeding Risk
DCB-HBR trial is prospective, multi-center, open-label, randomized controlled, noninferiority trial. The aim of the study is to compare clinical outcomes of drug-coated balloon (DCB) with drug-eluting stent (DES) for treatment of…
- Trial name
- DCB-HBR (NCT05221931)
- Testing
- Percutaneous coronary intervention
- Where
- 17 sites in South Korea
- Volunteers
- 1,359 people
- Sponsor
- Samsung Medical Center
Acute Coronary Syndrome, Atrial Fibrillation
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
The selection of the optimal antithrombotic therapy in patients with nonvalvular atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is challenging.
- Trial name
- EPIDAURUS (NCT04981041)
- Testing
- Prasugrel or Ticagrelor, Clopidogrel
- Where
- 37 sites in Austria, Germany
- Volunteers
- 602 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Percutaneous Coronary Intervention
Chewed Versus Integral Pill of Ticagrelor
Hypothesis The primary question the investigators propose to answer is whether all patients undergoing percutaneous coronary intervention (PCI) with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug…
- Trial name
- NCT03708588
- Testing
- Ticagrelor
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Wake Forest University Health Sciences
Coronary Artery Disease
Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention
The duration of dual antiplatelet treatment (i.e. asprin and clopidogrel) after drug-eluting stent implantation is highly debated.
- Trial name
- PRODIGY (NCT00611286)
- Testing
- clopidogrel treatment after bare metal stent implantation, clopidogrel after zotarolimus-eluting stent implantation, clopidogrel after paclitaxel-eluting stent implantation
- Where
- Italy
- Volunteers
- 1,700 people
- Sponsor
- Marco Valgimigli
PCI
Prognostic Role of Lipoprotein(a) in Elective Percutaneous Coronary Revascularization
The study investigates the role of Lipoprotein(a) [Lp(a)] levels in predicting cardiovascular risk and adverse events in patients undergoing elective percutaneous coronary intervention (PCI).
- Trial name
- NCT07197242
- Volunteers
- 156 people
- Sponsor
- Assiut University
Acute Myocardial Infarction, Percutaneous Coronary Intervention
Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction
The purpose of this study is to evaluate the efficacy of three different vasodilators including diltiazem, verapamil and nitroglycerin for reversal of no-reflow/slow-flow during direct percutaneous coronary intervention for acute…
- Trial name
- EDUCATE-AMI (NCT00712894)
- Testing
- Diltiazem, Verapamil, Nitroglycerin
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Fudan University
Bleeding
Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients
Bleeding occurring during percutaneous coronary interventions (PCI has now emerged as one of the most common complication of PCI and adversely affect in-hospital, short- and long-term outcome.As bivalirudin proved its…
- Trial name
- NAPLESIII (NCT01465503)
- Testing
- Bivalirudin, Unfractionated Heparin
- Where
- 2 sites in Italy
- Volunteers
- 837 people
- Sponsor
- Clinica Mediterranea
Atrial Fibrillation, Percutaneous Coronary Intervention
LAAO Versus NOAC in Patients with AF and PCI
Atrial fibrillation (AF) coincides with coronary artery disease (CAD) shared common risk factors and pathophysiologic pathways. CAD affects approximately 25% of AF patient according to the trial Atrial Fibrillation Follow-up…
- Trial name
- NCT05353140
- Testing
- The WATCHMAN/WATCHMAN FLX device, Rivaroxaban + Clopidogre, Aspirin + Clopidogrel
- Where
- China
- Volunteers
- 1,386 people
- Sponsor
- Xijing Hospital
Primary Percutaneous Coronary Intervention
Thin Versus Thicker Strut Thickness Stents in Primary Percutaneous Intervention
1. To evaluate clinical safety of the device in terms of Deaths, any stroke and Myocardial Infarction up to 1 year in both study groups to prove non inferiority of biomime stent 2.
- Trial name
- NCT06914089
- Testing
- The BioMime is an ultra-thin strut (65 µm) SES that uses a cobalt-chromium platform with a unique hybrid design of open cells in the mid segment and closed cells at the edges
- Where
- Egypt
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Assiut University
STEMI - ST Elevation Myocardial Infarction
Correlation Between Triglyceride Glucose Index and Residual SYNTAX Score in STEMI Patients Undergoing PPCI
The goal of this study To check correlation between triglyceride glucose (TyG) index and residual SYNTAX score (RSS) in STEMI patients undergoing PPCI. 2.
- Trial name
- NCT06642259
- Testing
- Echocardiography
- Volunteers
- 185 people
- Sponsor
- Assiut University
Acute Coronary Syndrome (ACS)
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
Aim of the randomized, open-label, multicenter ISAR-REACT 5 trial is to assess whether ticagrelor is superior to prasugrel in patients with acute coronary syndrome and planned invasive strategy in terms of clinical outcomes.
- Trial name
- ISAR-REACT 5 (NCT01944800)
- Testing
- Ticagrelor, Prasugrel
- Where
- 19 sites in Germany, Italy
- Volunteers
- 4,018 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Reperfusion Injury, STEMI
Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of IV administered elamipretide (also…
- Trial name
- EMBRACE (NCT01572909)
- Testing
- Bendavia (MTP-131)
- Where
- 30 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Stealth BioTherapeutics Inc.
Coronary Artery Disease, Ischemic Heart Disease
Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent
The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is to compare the safety and efficacy of the sirolimus eluting ORSIRO stent and the biolimus-eluting NOBORI stent in a population-based…
- Trial name
- SORT OUT VII (NCT01879358)
- Testing
- Drug-eluting stent
- Where
- Denmark
- Volunteers
- 2,314 people
- Sponsor
- Odense University Hospital
Obstructive Coronary Artery Disease, Obstructive Peripheral Artery Disease
Catheter-Based Treatment of Cardiovascular Disease
This study offers catheter-based treatment of heart or artery disease. This protocol permits treatment of patients with cardiovascular diseases who may not be eligible to participate in current research protocols.
- Conditions
- Obstructive Coronary Artery Disease, Obstructive Peripheral Artery Disease, Structural Heart Disease
- Trial name
- NCT00380016
- Testing
- Percutaneous Transluminal Angioplasty
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Coronary Syndrome, Acute Coronary Syndromes
Optimal LDL-C Target in High-risk Patients After PCI
Extensive evidence from epidemiological, genetic, and randomized controlled trials (RCTs) of lipid-lowering therapies has firmly established a causal relationship between low-density lipoprotein cholesterol (LDL-C) and…
- Conditions
- Chronic Coronary Syndrome, Acute Coronary Syndromes, Percutaneous Coronary Intervention, High Risk Patient
- Trial name
- REC-SAFETARGET (NCT06821711)
- Testing
- Intensive LDL-C control, Conventional LDL-C control
- Where
- China
- Volunteers
- 12,000 people
- Sponsor
- Xijing Hospital
Heart Function, Quality of Life
Functional and Clinical Benefits of PCI in Patients With CTO
The purpose of this study is to compare the diagnostic accuracy of hybrid imaging combining CTCA with low-dose stress-only SPECT vs.
- Trial name
- NCT01254253
- Testing
- Percutaneous coronary intervention, PCI
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xijing Hospital